Merck: positive CHMP opinion for Keytruda in NSCLC
The recommendation is based on the results of a phase III trial showing that Keytruda + chemotherapy followed by adjuvant Keytruda after surgical resection demonstrated clinically and statistically significant improvements in overall survival and event-free survival, compared with placebo + chemotherapy followed by adjuvant placebo in these patients.
The CHMP recommendation will now be considered by the European Commission for marketing authorization in the European Union (EU), with a final decision expected in the first half of 2024.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction